JP2018533954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533954A5 JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- expression
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194367 | 2015-11-12 | ||
| EP15194367.7 | 2015-11-12 | ||
| EP16189502.4 | 2016-09-19 | ||
| EP16189502 | 2016-09-19 | ||
| PCT/EP2016/077383 WO2017081223A1 (en) | 2015-11-12 | 2016-11-11 | Oligonucleotides for inducing paternal ube3a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136397A Division JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533954A JP2018533954A (ja) | 2018-11-22 |
| JP2018533954A5 true JP2018533954A5 (OSRAM) | 2020-04-09 |
| JP6751142B2 JP6751142B2 (ja) | 2020-09-02 |
Family
ID=57345910
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2018524194A Active JP6751142B2 (ja) | 2015-11-12 | 2016-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2018521433A Active JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521433A Active JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US10494633B2 (OSRAM) |
| EP (5) | EP4220360B9 (OSRAM) |
| JP (7) | JP2018533362A (OSRAM) |
| KR (4) | KR102482440B1 (OSRAM) |
| CN (5) | CN116064540A (OSRAM) |
| AU (4) | AU2016352836B2 (OSRAM) |
| CA (1) | CA3004799C (OSRAM) |
| CL (3) | CL2018001189A1 (OSRAM) |
| CO (1) | CO2018004550A2 (OSRAM) |
| CR (3) | CR20180264A (OSRAM) |
| DK (2) | DK3374509T3 (OSRAM) |
| ES (2) | ES2991800T3 (OSRAM) |
| FI (1) | FI4220360T3 (OSRAM) |
| HK (2) | HK1258309A1 (OSRAM) |
| HR (2) | HRP20241138T1 (OSRAM) |
| HU (2) | HUE053197T2 (OSRAM) |
| IL (3) | IL300119A (OSRAM) |
| LT (2) | LT4220360T (OSRAM) |
| MA (1) | MA67580B1 (OSRAM) |
| MX (4) | MX2018004978A (OSRAM) |
| PE (2) | PE20210451A1 (OSRAM) |
| PH (1) | PH12018501005A1 (OSRAM) |
| PL (2) | PL4220360T3 (OSRAM) |
| RS (2) | RS61529B9 (OSRAM) |
| RU (1) | RU2742007C2 (OSRAM) |
| SG (1) | SG11201803951QA (OSRAM) |
| SI (2) | SI4220360T1 (OSRAM) |
| UA (1) | UA125963C2 (OSRAM) |
| WO (3) | WO2017081254A1 (OSRAM) |
| ZA (1) | ZA201802494B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| BR112014001244A2 (pt) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | métodos para a síntese de ácidos nucléicos funcionalizados |
| EP2864479B1 (en) | 2012-06-25 | 2018-08-15 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| ES2862073T3 (es) | 2012-07-13 | 2021-10-06 | Wave Life Sciences Ltd | Grupo auxiliar asimétrico |
| CN112007045A (zh) | 2012-07-13 | 2020-12-01 | 波涛生命科学有限公司 | 手性控制 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| MA67580B1 (fr) | 2015-11-12 | 2024-09-30 | F. Hoffmann-La Roche Ag | Oligonucléotides pour induire l'expression de paternal ube3a |
| AU2018375807B2 (en) * | 2017-12-01 | 2025-04-10 | The Texas A&M University System | Angelman syndrome antisense treatment |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| AU2019344006B2 (en) | 2018-09-21 | 2025-11-27 | University Of Connecticut | Compositions and methods to restore paternal UBE3A gene expression in human Angelman Syndrome |
| CN113316722A (zh) * | 2019-01-17 | 2021-08-27 | 豪夫迈·罗氏有限公司 | E3泛素连接酶(ube3a)蛋白质靶标 |
| CA3130431A1 (en) * | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
| CR20210538A (es) | 2019-03-29 | 2021-12-06 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular ube3a-ats |
| EA202193214A1 (ru) | 2019-05-22 | 2022-03-14 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Гены ube3a и кассеты экспрессии и их использование |
| WO2020239714A1 (en) | 2019-05-28 | 2020-12-03 | F. Hoffmann-La Roche Ag | Method to generate monocytic progenitor cells |
| TW202204607A (zh) * | 2020-04-16 | 2022-02-01 | 英商羅斯林科技有限公司 | 誘導性多功能幹細胞(iPSC)之誘導 |
| JP2023529457A (ja) * | 2020-06-09 | 2023-07-10 | ロシュ イノベーション センター コペンハーゲン エーエス | 治療用ポリヌクレオチドに使用するためのグアノシン類似体 |
| WO2022158487A1 (ja) | 2021-01-21 | 2022-07-28 | 藤森工業株式会社 | 積層フィルムおよび包装袋 |
| WO2023217890A1 (en) | 2022-05-10 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting cfp-elk1 intergene region |
| WO2024227765A2 (en) | 2023-05-04 | 2024-11-07 | F. Hoffmann-La Roche Ag | Oligonucleotides capable of upregulating glucocerebrosidase expression |
| WO2025100980A1 (ko) * | 2023-11-08 | 2025-05-15 | 한국과학기술원 | Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도 |
| WO2025125542A1 (en) | 2023-12-15 | 2025-06-19 | F. Hoffmann-La Roche Ag | Intrathecal dosage method |
| WO2025217466A1 (en) * | 2024-04-11 | 2025-10-16 | Ultragenyx Pharmaceutical Inc. | Dosing regimens for antisense treatment of angelman syndrome |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373084A (en) | 1981-07-07 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom |
| AU2916292A (en) | 1991-10-24 | 1993-05-21 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| AU1853600A (en) * | 1999-01-06 | 2000-07-24 | Choong-Chin Liew | Method for the detection of gene transcripts in blood and uses thereof |
| RU2233844C2 (ru) | 1999-02-12 | 2004-08-10 | Санкио Компани Лимитед | Новые нуклеозидные и олигонуклеотидные аналоги |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US20020098511A1 (en) | 1999-12-02 | 2002-07-25 | Karen Heichman | Protein-protein interactions |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| WO2001092582A1 (en) * | 2000-06-01 | 2001-12-06 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
| US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
| EP2270024B1 (en) | 2001-06-21 | 2018-10-24 | Ionis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050124572A1 (en) | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
| EP1578927A2 (en) | 2002-08-14 | 2005-09-28 | Pharmacia Corporation | Antisense modulation of nav1.3 expression |
| JP2006500066A (ja) | 2002-09-25 | 2006-01-05 | ファルマシア・コーポレーション | ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節 |
| DK2284269T3 (en) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense design |
| GB2421029B (en) * | 2003-08-29 | 2008-04-09 | Wisconsin Alumni Res Found | Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| EP1984381B1 (en) | 2006-01-27 | 2010-09-29 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| WO2007131237A2 (en) | 2006-05-05 | 2007-11-15 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of ptp1b |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| WO2010096496A2 (en) * | 2009-02-17 | 2010-08-26 | Memorial Sloan-Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| JP5843775B2 (ja) * | 2009-10-13 | 2016-01-13 | ステムセル テクノロジーズ インコーポレーティッド | 幹細胞を分化させるための重量オスモル濃度の操作法 |
| NO2516648T3 (OSRAM) | 2009-12-23 | 2018-04-07 | ||
| US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー，インコーポレイテッド | Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療 |
| AU2011282217B2 (en) | 2010-07-19 | 2015-12-03 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (DMPK) expression |
| KR101788903B1 (ko) * | 2010-08-19 | 2017-10-23 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| EP3521451A1 (en) | 2010-11-17 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US9487752B2 (en) * | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| AU2012244816B2 (en) | 2011-04-20 | 2015-12-10 | Roche Glycart Ag | Method and constructs for the pH dependent passage of the blood-brain-barrier |
| EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| EP2864479B1 (en) * | 2012-06-25 | 2018-08-15 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| EP3119881B1 (en) * | 2014-03-21 | 2023-03-01 | FUJIFILM Cellular Dynamics, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
| MA67580B1 (fr) * | 2015-11-12 | 2024-09-30 | F. Hoffmann-La Roche Ag | Oligonucléotides pour induire l'expression de paternal ube3a |
| JP2020528739A (ja) | 2017-06-28 | 2020-10-01 | ユニヴァーシティ オブ サウス フロリダ | アンジェルマン症候群の遺伝子治療法のための改変ｕｂｅ３ａ遺伝子 |
| AU2018375807B2 (en) | 2017-12-01 | 2025-04-10 | The Texas A&M University System | Angelman syndrome antisense treatment |
| KR20200116088A (ko) | 2018-01-26 | 2020-10-08 | 에프. 호프만-라 로슈 아게 | 방사성 표지된 올리고뉴클레오티드 및 이의 제조 방법 |
| CR20210538A (es) | 2019-03-29 | 2021-12-06 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular ube3a-ats |
-
2016
- 2016-11-11 MA MA67580A patent/MA67580B1/fr unknown
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en not_active Ceased
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko active Active
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2016-11-11 EP EP23152543.7A patent/EP4220360B9/en active Active
- 2016-11-11 KR KR1020257024980A patent/KR20250121139A/ko active Pending
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 IL IL300119A patent/IL300119A/en unknown
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en not_active Withdrawn
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 HR HRP20241138TT patent/HRP20241138T1/hr unknown
- 2016-11-11 ES ES23152543T patent/ES2991800T3/es active Active
- 2016-11-11 LT LTEP23152543.7T patent/LT4220360T/lt unknown
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 SI SI201631843T patent/SI4220360T1/sl unknown
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en not_active Withdrawn
- 2016-11-11 PL PL23152543.7T patent/PL4220360T3/pl unknown
- 2016-11-11 KR KR1020227045154A patent/KR102840652B1/ko active Active
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active Active
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 FI FIEP23152543.7T patent/FI4220360T3/fi active
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 RS RS20241003A patent/RS66036B1/sr unknown
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja active Active
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en not_active Ceased
- 2016-11-11 DK DK23152543.7T patent/DK4220360T3/da active
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en not_active Ceased
- 2016-11-11 HU HUE23152543A patent/HUE067905T2/hu unknown
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
-
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en not_active Abandoned
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en not_active Abandoned
-
2019
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
-
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
-
2021
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
-
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
-
2023
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-01-25 AU AU2023200410A patent/AU2023200410B2/en active Active
- 2023-02-22 US US18/172,707 patent/US12259380B2/en active Active
- 2023-10-20 US US18/491,513 patent/US20250116656A2/en active Pending
-
2024
- 2024-11-11 JP JP2024196762A patent/JP2025024060A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533954A5 (OSRAM) | ||
| HRP20210227T1 (hr) | Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a | |
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| WO2013074974A3 (en) | Modified rnai agents | |
| JP2018519835A5 (OSRAM) | ||
| BR112013010525A2 (pt) | tratamento de hbv | |
| JP2017536366A5 (OSRAM) | ||
| JP2016522674A5 (OSRAM) | ||
| BR112015022876A2 (pt) | agente, composição farmacêutica e método para inibição da expressão do componente do complemento c5, uso do referido agente, vetor e célula. | |
| JP2018530530A5 (OSRAM) | ||
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| MX2020005680A (es) | Tratamiento antisentido del sindrome de angelman. | |
| JP2016520310A5 (OSRAM) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2021500016A5 (OSRAM) | ||
| RU2019101298A (ru) | Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 | |
| JP2011515357A5 (OSRAM) | ||
| JP2011519365A5 (OSRAM) | ||
| WO2013162350A3 (en) | Circular antiviral rna | |
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
| IL274363B2 (en) | Use of a specific siRNA against protein S for the treatment of hemophilia | |
| RU2016141263A (ru) | Аптамер для fgf2 и его применение | |
| WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |